Video summary

They Studied 83,000 Men on Testosterone| Here's What They Found

Main summary

Key takeaways

Science and Nature

Scientific Concepts, Discoveries, and Nature Phenomena Mentioned

Testosterone Replacement Therapy (TRT) and Safety in Older Men

  • For roughly two decades, an ongoing question has been whether TRT increases cardiovascular risk—such as heart attacks, strokes, and overall cardiovascular disease—particularly in older or high-risk men.
  • Earlier findings from the early 2000s (largely observational) suggested that in some groups of older men who already had cardiovascular disease, there was a reported spike in heart-attack risk within about 6 months of starting TRT.
  • Proposed interpretation in the video:
    • The early increase may reflect that men with already “bad hearts” and low testosterone may be started too aggressively.
    • This could lead to a sudden rise in activity and motivation (“sudden increase in activity and virility”), potentially stressing the cardiovascular system.

Dose Management / Titration Strategy

A cautionary approach suggested in the video:

  • Start TRT at lower doses
  • Gradually titrate upward

Coronary Artery Calcium Scoring (Agatston Score)

Mentioned as a pre-treatment risk stratification tool:

  • A CT-based test used to detect calcification in coronary arteries.
  • Calcification appears bright white on CT.
  • “Soft tissue” arteries are expected to show little or no calcium buildup.
  • Agatston score categories discussed:
    • 0: no coronary calcification → described as “pretty much clean” with very low risk
      • Note: non-calcified early plaque may still exist.
    • >100: higher risk → clinician may “go really slow.”
  • The video frames this as a “green light” / risk-calibration method for TRT decisions.

How TRT Was Studied: Randomized Trials vs Observational Studies

The video contrasts:

  • Randomized double-blind placebo-controlled non-inferiority trial
    • Designed primarily to assess safety, not to prove strong benefit.
  • Observational registry / longitudinal studies
    • Often report improved outcomes.

PubMed and Keyword-Based Literature Search

The described method for identifying relevant studies:

  • Use search terms such as:
    • “testosterone replacement”
    • “cardiovascular”
    • “myocardial infarction”
    • “mortality risk”
  • Conduct the search via PubMed.

Methodologies / Study Designs Outlined

Safety-Focused RCT (New England Journal of Medicine, 2023)

  • Design: multi-center, randomized, double-blind, placebo-controlled non-inferiority trial
  • Non-inferiority meaning:
    • Tests whether TRT is not worse than control regarding cardiovascular risk
    • Not designed to demonstrate strong benefit
  • Population:
    • ~5,200+ men
    • Ages 45–80
    • Pre-existing or high risk for cardiovascular disease
  • Eligibility / testosterone criterion:
    • Testosterone deficiency discussed as <300 ng/dL
  • Treatment:
    • 1.62% testosterone gel (topical)
    • Targeting levels roughly 350–750 ng/dL (as described)
  • Criticisms raised in the video:
    • Treatment duration varied widely: average ~21 months (±14 months)
    • Pharmacokinetic timing: topical gel peaks around ~6 hours and declines; studies may not standardize blood draw timing
    • Video argues that reference ranges and targets are set too low
  • Highlighted outcome:
    • No increased cardiovascular risk observed with the studied, lower-target regimen

Observational Registry Comparing Treated vs Untreated (Traish et al., 2017)

  • Design: real-world observational registry; treated vs control group who opted out
  • Population:
    • 656 men
    • Average age ~60 (range ~53–67)
    • Low testosterone <300 ng/dL
  • Treatment:
    • Injectable testosterone undecanoate (described as long-lasting ester)
    • Dosing described as low by the speaker (e.g., 1000 mg every 12 weeks)
  • Follow-up:
    • Mean ~7 years
  • Primary outcome:
    • Mortality
  • Result emphasized:
    • Lower deaths in the TRT group vs untreated group
    • Cardiovascular-related and non-cardiovascular causes discussed

Long-Term Effects in Older Hypogonadal Men (Andrologia, 2016)

  • Design: long-term follow-up (up to ~10 years) in a cohort
  • Population:
    • 115 hypogonadal elderly men (older; ~60 years ±)
  • Treatment:
    • Testosterone undecanoate every 12 weeks (described)
  • Outcomes emphasized:
    • Hemoglobin A1c (HbA1c) reduction
    • Improvements in diabetes/prediabetes classification (as described)
    • Blood pressure reductions (systolic/diastolic)

European Heart Journal (2015) and Related Large-Scale Association

  • Claim described: normalization of testosterone associated with reduced incidence of myocardial infarction and mortality
  • Population: 83,000 male veterans
  • Study type: described as retrospective/observational (not randomized prospective)

European Journal of Endocrinology (2013): Type 2 Diabetes Subgroup

  • Design: European study combining observational/real-world clinical practice elements
  • Population:
    • 581 men with type 2 diabetes
    • Low testosterone <300 ng/dL
  • Treatment mix described:
    • Testosterone gel majority (reported ~85.9%)
    • Testosterone undecanoate injection minority (~14%)
  • Follow-up: ~6 years average
  • Outcomes emphasized:
    • Higher mortality in lower-testosterone groups vs higher-testosterone groups
    • Lower mortality among treated vs untreated groups (reported percentages)

Outcomes / Cardiovascular-Metabolic Effects Asserted in the Video

  • Cardiovascular safety framing:
    • The RCT (NEJM 2023) is presented as showing no increased cardiovascular risk with lower-dose TRT targets.
  • Mortality and event reduction assertions:
    • Lower all-cause mortality and cardiovascular events in men with low testosterone receiving TRT (as described by the speaker).
  • Metabolic/endocrine effects asserted:
    • HbA1c reduction (from diabetic-range average ~6.4% toward ~5.6% in one described study)
    • Decreases in systolic and diastolic blood pressure
    • Improvements in diabetes status / metabolic syndrome measures (as described)

Researchers / Sources Featured

  • Dr. Ty Vincent (speaker)
  • PubMed (used as a literature source; not an individual researcher)
  • New England Journal of Medicine (2023) (journal; specific trial not named in subtitles)
  • Cleveland Clinic (referenced via a clinician speaker)
  • Traish (author named)
  • Journal of Cardiovascular Pharmacology and Therapeutics (2017) (where Traish article is said to be published)
  • Andrologia (2016) (long-term study described)
  • European Heart Journal (2015) (83,000 veterans study described)
  • European Journal of Endocrinology (2013) (type 2 diabetes study described)
  • LabCorp (reference ranges mentioned; not a researcher)

Original video